196 related articles for article (PubMed ID: 19781099)
1. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting.
Straka RJ; Liu LZ; Girase PS; DeLorenzo A; Chapman RH
Cardiovasc Diabetol; 2009 Sep; 8():53. PubMed ID: 19781099
[TBL] [Abstract][Full Text] [Related]
2. Determining initial and follow-up costs of cardiovascular events in a US managed care population.
Chapman RH; Liu LZ; Girase PG; Straka RJ
BMC Cardiovasc Disord; 2011 Mar; 11():11. PubMed ID: 21410963
[TBL] [Abstract][Full Text] [Related]
3. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
[TBL] [Abstract][Full Text] [Related]
4. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
[TBL] [Abstract][Full Text] [Related]
5. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
Laliberté F; Bookhart BK; Vekeman F; Corral M; Duh MS; Bailey RA; Piech CT; Lefebvre P
J Manag Care Pharm; 2009 May; 15(4):312-22. PubMed ID: 19422271
[TBL] [Abstract][Full Text] [Related]
6. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.
Pelletier EM; Smith PJ; Boye KS; Misurski DA; Tunis SL; Minshall ME
Appl Health Econ Health Policy; 2008; 6(2-3):103-12. PubMed ID: 19231904
[TBL] [Abstract][Full Text] [Related]
7. Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations.
Coutinho AD; Raju AD; Wang W; Stafkey-Mailey D; Shetty S; Sander SD
Curr Med Res Opin; 2018 Jun; 34(6):1005-1012. PubMed ID: 29378486
[TBL] [Abstract][Full Text] [Related]
8. Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both.
Nguyen C; Luthra R; Kuti E; Willey VJ
Curr Med Res Opin; 2020 Dec; 36(12):1927-1938. PubMed ID: 33023310
[TBL] [Abstract][Full Text] [Related]
9. Medical costs of managed care in patients with type 2 diabetes mellitus.
Bhattacharyya SK; Else BA
Clin Ther; 1999 Dec; 21(12):2131-42. PubMed ID: 10645758
[TBL] [Abstract][Full Text] [Related]
10. Health care resource utilization and costs associated with nonfatal major adverse cardiovascular events.
Korsnes JS; Davis KL; Ariely R; Bell CF; Mitra D
J Manag Care Spec Pharm; 2015 Jun; 21(6):443-50. PubMed ID: 26011546
[TBL] [Abstract][Full Text] [Related]
11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
12. Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Reed SD; Li Y; Dakin HA; Becker F; Leal J; Gustavson SM; Kartman B; Wittbrodt E; Mentz RJ; Pagidipati NJ; Bethel MA; Gray AM; Holman RR; Hernandez AF;
Diabetes Care; 2020 Feb; 43(2):374-381. PubMed ID: 31806653
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
14. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis.
Pelletier EM; Shim B; Ben-Joseph R; Caro JJ
Pharmacoeconomics; 2009; 27(6):479-90. PubMed ID: 19640011
[TBL] [Abstract][Full Text] [Related]
15. Health care utilization and costs in type 2 diabetes mellitus and their association with renal impairment.
Burke J; Kovacs B; Borton L; Sander S
Postgrad Med; 2012 Mar; 124(2):77-91. PubMed ID: 22437218
[TBL] [Abstract][Full Text] [Related]
16. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors.
Amin AN; Jhaveri M; Lin J
Adv Ther; 2011 Oct; 28(10):907-26. PubMed ID: 21971681
[TBL] [Abstract][Full Text] [Related]
17. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis.
Brown JB; Nichols GA; Glauber HS; Bakst AW
Diabetes Care; 1999 Jul; 22(7):1116-24. PubMed ID: 10388977
[TBL] [Abstract][Full Text] [Related]
18. The effect of a diabetes collaborative care management program on clinical and economic outcomes in patients with type 2 diabetes.
McAdam-Marx C; Dahal A; Jennings B; Singhal M; Gunning K
J Manag Care Spec Pharm; 2015 Jun; 21(6):452-68. PubMed ID: 26011547
[TBL] [Abstract][Full Text] [Related]
19. Additional stroke-related and non-stroke-related cardiovascular costs and hospitalizations in managed-care patients after ischemic stroke.
Roberts CS; Gorelick PB; Ye X; Harley C; Goldberg GA
Stroke; 2009 Apr; 40(4):1425-32. PubMed ID: 19246698
[TBL] [Abstract][Full Text] [Related]
20. Elevated Costs and Healthcare Resource Utilization in Patients With Type 2 Diabetes and Established Cardiovascular Disease in Israel.
Melzer Cohen C; Hallén N; Chodick G; Bourvine L; Waner T; Karasik A
Value Health Reg Issues; 2020 Sep; 22():83-92. PubMed ID: 32798839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
